To prove the feasibility of using fluorescent probes for stratifying NSCLC patients for EGFR-TKI therapy, we set out to rational design EGFR-TKI-based probes (Fig. 1a). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.